Metastatic pancreatic cancer responds well to treatment with combination of daraxonrasib and chemotherapy
Daraxonrasib combined with chemotherapy caused substantial tumor shrinkage in patients with pancreatic cancer that had spread to other parts of the body, according to new results from a Phase I/II clinical trial.
A new Phase I/II clinical trial has shown promising results for a combination of daraxonrasib and chemotherapy in treating metastatic pancreatic cancer. The trial, presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain, found that the drug combination led to substantial tumor shrinkage in patients who had not previously received treatment for metastatic disease.
Dr. Wungki Park, the principal investigator, highlighted the encouraging prolonged disease control and potentially transformative advance in first-line treatment for patients with metastatic pancreatic cancer. The trial involved 61 patients, with the median follow-up time being 18.3 months. Tumor shrinkage or disappearance was observed in 60.7% of patients, with a median progression-free survival of 12.8 months.
This represents a significant improvement over the high end of historical overall survival for conventional chemotherapy, which ranges from 8.5-11.1 months.
Brief written by urgent.news from Medical Xpress's own syndicated text. Machine-written — may contain errors; check the original before relying on it.